CIK 0001739410 · <br>Emerging growth company
Rallybio Corp
Sign in to watch- Ticker
- RLYB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851083789
- Phone
- 203- 859-3820
- Business address
- 234 CHURCH STREET, SUITE 1020, NEW HAVEN, CT, 06510
- Former names
- Rallybio Holdings, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,608
- in 1 filing
Net −$9,608. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-11 | ADAR1 Capital Management, LLC 10% owner | Purchase | +5,100 | $14.00 | $71K | 784,884 |
| 2026-05-11 | ADAR1 Capital Management, LLC 10% owner | Purchase | +25,000 | $14.00 | $350K | 809,884 |
| 2026-05-11 | ADAR1 Capital Management, LLC 10% owner | Purchase | +19,900 | $14.00 | $279K | 829,784 |
| 2026-05-05 | ADAR1 Capital Management, LLC 10% owner | Purchase | +35,101 | $14.00 | $491K | 779,784 |
| 2026-05-04 | ADAR1 Capital Management, LLC 10% owner | Purchase | +3,900 | $13.90 | $54K | 627,779 |
| 2026-05-04 | ADAR1 Capital Management, LLC 10% owner | Purchase | +116,904 | $13.97 | $1.6M | 744,683 |
| 2026-02-23 | Lieber Jonathan I Chief Financial Officer | Sale | −789 | $5.06 | $4K | 4,115 |
| 2026-02-18 | Lieber Jonathan I Chief Financial Officer | Grant or award | +2,500 | 4,904 | ||
| 2026-02-18 | HUNT RONALD Director | Grant or award · Option (Right to Buy) | +14,305 | $3.60 | $51K | 14,305 |
| 2026-02-18 | MACKAY MARTIN Director | Grant or award · Option (Right to Buy) | +18,055 | $3.60 | $65K | 18,055 |
| 2025-05-13 | Boudreau Helen M Director | Grant or award · Option (Right to Buy) | +28,500 | 28,500 | ||
| 2025-05-13 | Chung Wendy Director | Grant or award · Option (Right to Buy) | +28,500 | 28,500 | ||
| 2025-05-13 | HUNT RONALD Director | Grant or award · Option (Right to Buy) | +28,500 | 28,500 | ||
| 2025-05-13 | Nash Christine A Director | Grant or award · Option (Right to Buy) | +28,500 | 28,500 | ||
| 2025-05-13 | Hopfner Robert Lorne Director | Grant or award · Option (Right to Buy) | +28,500 | 28,500 | ||
| 2025-05-13 | Soteropoulos Paula Director | Grant or award · Option (Right to Buy) | +28,500 | 28,500 | ||
| 2025-05-13 | Liu Hui Director | Grant or award · Option (Right to Buy) | +28,500 | 28,500 | ||
| 2025-05-13 | MACKAY MARTIN Director | Grant or award · Option (Right to Buy) | +28,500 | 28,500 | ||
| 2025-02-14 | Uden Stephen Chief Executive Officer | Grant or award · Option (Right to Buy) | +453,700 | 453,700 | ||
| 2025-02-14 | Ryder Steven Chief Medical Officer | Grant or award · Option (Right to Buy) | +180,000 | 180,000 |
Page 4 of 11 · 216 trades